Consumer Cyclical -
Specialty Retail - NASDAQ - US
$ 500.27
-1.19 %
$ 18.6 B
Market Cap
34.22
P/E
1. INTRINSIC VALUE
Balance Sheet
Casey's General Stores, Inc.
| Current Assets | 1.01 B |
| Cash & Short-Term Investments | 327 M |
| Receivables | 182 M |
| Other Current Assets | 505 M |
| Non-Current Assets | 7.2 B |
| Long-Term Investments | 0 |
| PP&E | 5.83 B |
| Other Non-Current Assets | 1.36 B |
| Current Liabilities | 1.1 B |
| Accounts Payable | 620 M |
| Short-Term Debt | 94.9 M |
| Other Current Liabilities | 386 M |
| Non-Current Liabilities | 3.6 B |
| Long-Term Debt | 2.85 B |
| Other Non-Current Liabilities | 749 M |
EFFICIENCY
Earnings Waterfall
Casey's General Stores, Inc.
| Revenue | 15.9 B |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 2.55 B |
| Operating Income | 0 |
| Other Expenses | -547 M |
| Net Income | 547 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Casey's General Stores, Inc.
| Net Income | 547 M |
| Depreciation & Amortization | 404 M |
| Capital Expenditures | -506 M |
| Stock-Based Compensation | 47.7 M |
| Change in Working Capital | 0 |
| Others | 0 |
| Free Cash Flow | 585 M |
Wall Street Analysts Price Targets
Casey's General Stores, Inc.
Wall Street analysts predict an average 1-year price target for CASY of $418 , with forecasts ranging from
a
low of
$360 to a high of $454 .
CASY Lowest Price Target
Wall Street Target
360 USD
-28.04%
CASY Average Price Target
Wall Street Target
418 USD
-16.41%
CASY Highest Price Target
Wall Street Target
454 USD
-9.25%
4. DIVIDEND
ANALYSIS
0.11%
DIVIDEND YIELD
0.57 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Casey's General Stores, Inc.
Sold
0-3 MONTHS
27.9 M USD 8
3-6 MONTHS
0 USD 0
6-9 MONTHS
192 K USD 1
9-12 MONTHS
8.27 M USD 3
Bought
0 USD 0
0-3 MONTHS
298 K USD 1
3-6 MONTHS
100 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Trade Tracker: Adobe, Suncor Energy, Enbridge, Casey's and the EIS
The Investment Committee share their latest portfolio moves.
youtube.com
- 6 days ago
Why Casey's General Stores Stock Skyrocketed This Week
Shares of Midwestern pizza and convenience store chain Casey's General Stores (CASY 1.09%) were 13% higher this week as of 12:30 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence.
fool.com
- 1 week ago
These Analysts Boost Their Forecasts On Casey's General Stores Following Upbeat Earnings
Casey's General Stores Inc. CASY posted better-than-expected earnings for its fourth quarter on Monday.
benzinga.com
- 1 week ago
4 Stocks to Watch That Recently Hiked Dividends Amid Economic Woes
UTZ, SUI, EOG and CASY just raised dividends, offering stability as markets wrestle with tariff fears and rate-cut uncertainty.
zacks.com
- 1 week ago
26,324 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Squarepoint Ops LLC
Squarepoint Ops LLC acquired a new position in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,324 shares of the company’s stock, valued at approximately $44,000. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Nautilus Biotechnology during the fourth quarter worth about $28,000. Cubist Systematic Strategies LLC bought a new position in Nautilus Biotechnology during the fourth quarter worth about $34,000. SG Americas Securities LLC boosted its position in Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares during the period. Palumbo Wealth Management LLC boosted its position in shares of Nautilus Biotechnology by 45.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock valued at $48,000 after acquiring an additional 8,888 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $63,000. Institutional investors own 50.71% of the company’s stock. Nautilus Biotechnology Stock Down 2.7% Shares of NASDAQ NAUT opened at $0.75 on Wednesday. Nautilus Biotechnology, Inc. has a 52 week low of $0.66 and a 52 week high of $3.09. The company has a market cap of $94.74 million, a price-to-earnings ratio of -1.34 and a beta of 1.43. The firm’s fifty day moving average is $0.75 and its 200 day moving average is $1.32. Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. Equities research analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year. Insider Activity at Nautilus Biotechnology In other Nautilus Biotechnology news, CEO Sujal M. Patel purchased 53,300 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the purchase, the chief executive officer now directly owns 10,117,788 shares of the company’s stock, valued at $10,016,610.12. This trade represents a 0.53% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders purchased 81,800 shares of company stock worth $74,172. 41.10% of the stock is owned by company insiders. Wall Street Analyst Weigh In Separately, Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a research report on Friday, February 28th. Get Our Latest Stock Analysis on NAUT Nautilus Biotechnology Company Profile (Free Report) Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. Read More Five stocks we like better than Nautilus Biotechnology What is the Euro STOXX 50 Index? AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What Does Downgrade Mean in Investing? Casey’s Surges on Strong Q4, More Gains Likely Ahead What does consumer price index measure? Government Mandate Sends eVTOL Stocks Flying
https://www.defenseworld.net
- 1 week ago
Squarepoint Ops LLC Makes New Investment in Northern Dynasty Minerals Ltd. (NYSEAMERICAN:NAK)
Squarepoint Ops LLC bought a new position in Northern Dynasty Minerals Ltd. (NYSEAMERICAN:NAK – Free Report) (TSE:NDM) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 76,468 shares of the mining company’s stock, valued at approximately $44,000. A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Allegheny Financial Group bought a new position in shares of Northern Dynasty Minerals during the 4th quarter valued at $30,000. Game Plan Financial Advisors LLC raised its holdings in shares of Northern Dynasty Minerals by 29.5% during the 4th quarter. Game Plan Financial Advisors LLC now owns 79,000 shares of the mining company’s stock valued at $45,000 after purchasing an additional 18,000 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Northern Dynasty Minerals by 1,042.0% during the 4th quarter. Bank of America Corp DE now owns 138,092 shares of the mining company’s stock valued at $80,000 after purchasing an additional 126,000 shares in the last quarter. Two Sigma Advisers LP bought a new position in shares of Northern Dynasty Minerals during the 4th quarter valued at $82,000. Finally, Tidal Investments LLC bought a new position in shares of Northern Dynasty Minerals during the 4th quarter valued at $143,000. Hedge funds and other institutional investors own 10.55% of the company’s stock. Wall Street Analysts Forecast Growth Separately, Wall Street Zen raised shares of Northern Dynasty Minerals to a “sell” rating in a research report on Wednesday, May 21st. Read Our Latest Report on Northern Dynasty Minerals Northern Dynasty Minerals Stock Up 3.1% NYSEAMERICAN NAK opened at $1.32 on Wednesday. The stock has a market cap of $710.20 million, a P/E ratio of -33.00 and a beta of 0.51. The company’s 50-day simple moving average is $1.05 and its 200 day simple moving average is $0.72. Northern Dynasty Minerals Ltd. has a twelve month low of $0.27 and a twelve month high of $1.35. Northern Dynasty Minerals Profile (Free Report) Northern Dynasty Minerals Ltd. engages in the exploration of mineral properties in the United States. It holds a 100% interest in the Pebble Copper-Gold-Molybdenum-Silver-Rhenium project comprising 1,840 mineral claims that covers an area of approximately 274 square miles located in southwest Alaska, the United States. Read More Five stocks we like better than Northern Dynasty Minerals The 3 Best Blue-Chip Stocks to Buy Now AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What Are the U.K. Market Holidays? How to Invest and Trade Casey’s Surges on Strong Q4, More Gains Likely Ahead 3 REITs to Buy and Hold for the Long Term Government Mandate Sends eVTOL Stocks Flying
https://www.defenseworld.net
- 1 week ago
Squarepoint Ops LLC Takes Position in U.S. Gold Corp. (NASDAQ:USAU)
Squarepoint Ops LLC purchased a new position in shares of U.S. Gold Corp. (NASDAQ:USAU – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,292 shares of the technology company’s stock, valued at approximately $69,000. Squarepoint Ops LLC owned 0.09% of U.S. Gold at the end of the most recent reporting period. Several other hedge funds have also recently modified their holdings of the stock. Occudo Quantitative Strategies LP acquired a new stake in U.S. Gold in the fourth quarter valued at $73,000. JPMorgan Chase & Co. raised its stake in U.S. Gold by 93.8% in the 4th quarter. JPMorgan Chase & Co. now owns 14,117 shares of the technology company’s stock valued at $87,000 after purchasing an additional 6,831 shares during the last quarter. Walleye Capital LLC purchased a new stake in U.S. Gold in the 4th quarter valued at about $114,000. Cubist Systematic Strategies LLC purchased a new stake in U.S. Gold in the 4th quarter valued at about $182,000. Finally, Commonwealth Equity Services LLC purchased a new stake in U.S. Gold in the 4th quarter valued at about $190,000. 6.64% of the stock is owned by institutional investors and hedge funds. U.S. Gold Stock Down 2.9% Shares of U.S. Gold stock opened at $13.16 on Wednesday. The firm has a market cap of $167.04 million, a price-to-earnings ratio of -13.16 and a beta of 1.32. The business has a fifty day simple moving average of $10.57 and a 200-day simple moving average of $8.84. U.S. Gold Corp. has a fifty-two week low of $4.71 and a fifty-two week high of $14.39. U.S. Gold (NASDAQ:USAU – Get Free Report) last announced its earnings results on Monday, March 17th. The technology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.27). Analysts anticipate that U.S. Gold Corp. will post -0.95 earnings per share for the current fiscal year. Analyst Upgrades and Downgrades Several equities analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective (up from $14.00) on shares of U.S. Gold in a research note on Friday, May 23rd. Roth Capital reaffirmed a “buy” rating on shares of U.S. Gold in a research report on Tuesday, May 6th. Read Our Latest Stock Report on USAU About U.S. Gold (Free Report) U.S. Gold Corp. engages in the exploration and development of gold and precious metals in the United States. It also explores for copper and silver deposits. The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 601 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 77 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho. See Also Five stocks we like better than U.S. Gold Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What Makes a Stock a Good Dividend Stock? Casey’s Surges on Strong Q4, More Gains Likely Ahead What is the Dow Jones Industrial Average (DJIA)? Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding USAU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for U.S. Gold Corp. (NASDAQ:USAU – Free Report).
https://www.defenseworld.net
- 1 week ago
Squarepoint Ops LLC Has $65,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS)
Squarepoint Ops LLC trimmed its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 51.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,944 shares of the company’s stock after selling 75,013 shares during the period. Squarepoint Ops LLC’s holdings in Gossamer Bio were worth $65,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GOSS. Two Sigma Investments LP grew its position in shares of Gossamer Bio by 41.3% in the fourth quarter. Two Sigma Investments LP now owns 891,279 shares of the company’s stock valued at $806,000 after purchasing an additional 260,318 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Gossamer Bio by 44.7% in the 4th quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company’s stock valued at $1,047,000 after buying an additional 357,500 shares during the last quarter. Octagon Capital Advisors LP grew its holdings in Gossamer Bio by 99.7% in the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after buying an additional 9,162,117 shares during the last quarter. Millennium Management LLC grew its holdings in Gossamer Bio by 14.6% in the 4th quarter. Millennium Management LLC now owns 3,586,067 shares of the company’s stock valued at $3,244,000 after buying an additional 457,179 shares during the last quarter. Finally, Lazard Asset Management LLC grew its holdings in Gossamer Bio by 7,992.6% in the 4th quarter. Lazard Asset Management LLC now owns 107,470 shares of the company’s stock valued at $97,000 after buying an additional 106,142 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds. Gossamer Bio Price Performance Shares of GOSS stock opened at $1.25 on Wednesday. Gossamer Bio, Inc. has a 12-month low of $0.51 and a 12-month high of $1.55. The firm has a market capitalization of $284.13 million, a price-to-earnings ratio of -3.91 and a beta of 1.85. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a fifty day moving average of $1.03 and a 200-day moving average of $1.04. Gossamer Bio (NASDAQ:GOSS – Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. On average, equities research analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year. Wall Street Analysts Forecast Growth GOSS has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, May 16th. Wedbush reissued an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Check Out Our Latest Report on GOSS About Gossamer Bio (Free Report) Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. See Also Five stocks we like better than Gossamer Bio How to Profit From Growth Investing AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway High Dividend REITs: Are They an Ideal Way to Diversify? Casey’s Surges on Strong Q4, More Gains Likely Ahead What Are Dividend Achievers? An Introduction Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding GOSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report).
https://www.defenseworld.net
- 1 week ago
19,009 Shares in Q32 Bio Inc. (NASDAQ:QTTB) Acquired by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,009 shares of the company’s stock, valued at approximately $65,000. Squarepoint Ops LLC owned about 0.16% of Q32 Bio as of its most recent SEC filing. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in QTTB. Rhumbline Advisers grew its holdings in Q32 Bio by 1,164.3% during the fourth quarter. Rhumbline Advisers now owns 105,544 shares of the company’s stock worth $363,000 after acquiring an additional 97,196 shares during the period. Bleakley Financial Group LLC acquired a new stake in shares of Q32 Bio during the fourth quarter valued at $149,000. Raymond James Financial Inc. acquired a new stake in shares of Q32 Bio during the fourth quarter valued at $37,000. Cubist Systematic Strategies LLC purchased a new position in Q32 Bio during the fourth quarter worth about $42,000. Finally, Deutsche Bank AG lifted its position in Q32 Bio by 699.8% during the fourth quarter. Deutsche Bank AG now owns 25,018 shares of the company’s stock worth $86,000 after buying an additional 21,890 shares during the period. Hedge funds and other institutional investors own 31.32% of the company’s stock. Analyst Ratings Changes A number of equities analysts have recently commented on the company. Piper Sandler downgraded Q32 Bio from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $20.00 to $4.00 in a report on Tuesday, February 11th. BMO Capital Markets downgraded Q32 Bio from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $22.00 to $3.00 in a report on Tuesday, February 11th. Finally, Wells Fargo & Company cut their price objective on Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating on the stock in a report on Wednesday, March 12th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.71. Read Our Latest Report on QTTB Q32 Bio Price Performance Shares of NASDAQ:QTTB opened at $1.68 on Wednesday. Q32 Bio Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $53.79. The business has a 50-day moving average of $1.75 and a two-hundred day moving average of $4.33. The stock has a market capitalization of $20.49 million, a P/E ratio of -0.12 and a beta of -0.03. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. Q32 Bio (NASDAQ:QTTB – Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.33. On average, equities research analysts predict that Q32 Bio Inc. will post -12.32 EPS for the current fiscal year. Q32 Bio Company Profile (Free Report) Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. See Also Five stocks we like better than Q32 Bio Quiet Period Expirations Explained AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What is a Dividend Harvesting Strategy and How Can Investors Profit from it? Casey’s Surges on Strong Q4, More Gains Likely Ahead What is a Secondary Public Offering? What Investors Need to Know Government Mandate Sends eVTOL Stocks Flying
https://www.defenseworld.net
- 1 week ago
Squarepoint Ops LLC Takes $68,000 Position in InnovAge Holding Corp. (NASDAQ:INNV)
Squarepoint Ops LLC purchased a new stake in InnovAge Holding Corp. (NASDAQ:INNV – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 17,272 shares of the company’s stock, valued at approximately $68,000. Other hedge funds have also recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in shares of InnovAge by 42.4% in the 4th quarter. Bank of America Corp DE now owns 19,945 shares of the company’s stock valued at $78,000 after purchasing an additional 5,936 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in InnovAge during the 4th quarter worth $123,000. Jane Street Group LLC grew its position in InnovAge by 230.6% during the 4th quarter. Jane Street Group LLC now owns 39,398 shares of the company’s stock worth $155,000 after purchasing an additional 27,481 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of InnovAge by 4.7% in the fourth quarter. Northern Trust Corp now owns 330,099 shares of the company’s stock valued at $1,297,000 after acquiring an additional 14,900 shares in the last quarter. Finally, Topline Capital Management LLC purchased a new stake in shares of InnovAge in the fourth quarter valued at about $231,000. Hedge funds and other institutional investors own 12.26% of the company’s stock. Insider Transactions at InnovAge In other news, Director Richard C. Zoretic acquired 8,450 shares of the business’s stock in a transaction on Friday, May 30th. The shares were purchased at an average price of $4.08 per share, for a total transaction of $34,476.00. Following the completion of the purchase, the director now directly owns 68,494 shares of the company’s stock, valued at $279,455.52. This represents a 14.07% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael Anthony Scarbrough purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 9th. The stock was bought at an average cost of $3.55 per share, for a total transaction of $35,500.00. Following the acquisition, the chief operating officer now owns 10,000 shares in the company, valued at approximately $35,500. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders purchased 71,653 shares of company stock valued at $281,922 over the last quarter. Company insiders own 1.40% of the company’s stock. InnovAge Stock Down 1.0% INNV stock opened at $3.81 on Wednesday. The company has a market cap of $514.40 million, a P/E ratio of -20.05 and a beta of 0.55. InnovAge Holding Corp. has a 52 week low of $2.60 and a 52 week high of $6.69. The company’s 50-day moving average price is $3.42 and its 200 day moving average price is $3.62. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.27. InnovAge (NASDAQ:INNV – Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The firm had revenue of $218.14 million during the quarter, compared to analysts’ expectations of $214.09 million. InnovAge had a negative return on equity of 9.45% and a negative net margin of 3.19%. On average, research analysts expect that InnovAge Holding Corp. will post -0.12 earnings per share for the current fiscal year. InnovAge Profile (Free Report) InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. See Also Five stocks we like better than InnovAge Stock Market Sectors: What Are They and How Many Are There? AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What Are Earnings Reports? Casey’s Surges on Strong Q4, More Gains Likely Ahead What is an Earnings Surprise? Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding INNV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InnovAge Holding Corp. (NASDAQ:INNV – Free Report).
https://www.defenseworld.net
- 1 week ago
26,770 Shares in Aterian, Inc. (NASDAQ:ATER) Bought by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new position in Aterian, Inc. (NASDAQ:ATER – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 26,770 shares of the company’s stock, valued at approximately $64,000. Squarepoint Ops LLC owned 0.31% of Aterian as of its most recent filing with the SEC. Separately, Renaissance Technologies LLC boosted its holdings in shares of Aterian by 93.3% during the 4th quarter. Renaissance Technologies LLC now owns 45,493 shares of the company’s stock valued at $109,000 after purchasing an additional 21,958 shares during the last quarter. Institutional investors and hedge funds own 7.02% of the company’s stock. Insider Transactions at Aterian In other news, insider Phillip Lepper sold 27,532 shares of the company’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $1.65, for a total transaction of $45,427.80. Following the transaction, the insider now directly owns 150,402 shares of the company’s stock, valued at approximately $248,163.30. This represents a 15.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.70% of the company’s stock. Aterian Price Performance Shares of NASDAQ:ATER opened at $1.41 on Wednesday. Aterian, Inc. has a 1 year low of $1.36 and a 1 year high of $3.84. The business has a 50 day simple moving average of $1.74 and a two-hundred day simple moving average of $2.10. The firm has a market capitalization of $12.34 million, a PE ratio of -0.52 and a beta of 0.37. Aterian (NASDAQ:ATER – Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.17. The firm had revenue of $15.36 million during the quarter, compared to analyst estimates of $14.95 million. Aterian had a negative return on equity of 56.01% and a negative net margin of 17.05%. Aterian declared that its board has authorized a share buyback plan on Tuesday, March 18th that authorizes the company to buyback $3.00 million in shares. This buyback authorization authorizes the company to buy up to 16.2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued. Analyst Upgrades and Downgrades Several research analysts have commented on ATER shares. Alliance Global Partners downgraded shares of Aterian from a “buy” rating to a “neutral” rating in a report on Wednesday, April 23rd. Industrial Alliance Securities set a $4.00 price target on shares of Aterian in a report on Wednesday, March 19th. Get Our Latest Analysis on ATER Aterian Profile (Free Report) Aterian, Inc, together with its subsidiaries, operates as a technology-enabled consumer products company in North America and internationally. Its platform offers home and kitchen appliances; kitchenware; cooling and air quality appliances, such as dehumidifiers; health and beauty products; and essential oils under the Squatty Potty, hOmeLabs, Mueller, Pursteam, Healing Solutions, and Photo Paper Direct brand names. See Also Five stocks we like better than Aterian 3 Healthcare Dividend Stocks to Buy AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Growth Stocks: What They Are, Examples and How to Invest Casey’s Surges on Strong Q4, More Gains Likely Ahead 3 Fintech Stocks With Good 2021 Prospects Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding ATER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aterian, Inc. (NASDAQ:ATER – Free Report).
https://www.defenseworld.net
- 1 week ago
Squarepoint Ops LLC Buys New Position in Abeona Therapeutics Inc (NASDAQ:ABEO)
Squarepoint Ops LLC bought a new position in Abeona Therapeutics Inc (NASDAQ:ABEO – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,028 shares of the biopharmaceutical company’s stock, valued at approximately $67,000. Other institutional investors and hedge funds have also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Abeona Therapeutics by 20.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after buying an additional 652,366 shares in the last quarter. 683 Capital Management LLC raised its position in Abeona Therapeutics by 17.3% in the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after buying an additional 116,845 shares during the last quarter. Bank of America Corp DE raised its position in Abeona Therapeutics by 16.7% in the 4th quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company’s stock worth $1,473,000 after buying an additional 37,774 shares during the last quarter. Northern Trust Corp grew its stake in shares of Abeona Therapeutics by 6.6% during the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 11,478 shares during the period. Finally, Jane Street Group LLC grew its stake in shares of Abeona Therapeutics by 894.8% during the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock valued at $732,000 after purchasing an additional 118,262 shares during the period. Institutional investors own 80.56% of the company’s stock. Abeona Therapeutics Stock Performance Shares of NASDAQ:ABEO opened at $6.46 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The business’s 50 day moving average price is $5.62 and its 200-day moving average price is $5.58. The firm has a market capitalization of $330.47 million, a PE ratio of -2.40 and a beta of 1.54. Abeona Therapeutics Inc has a 1 year low of $3.93 and a 1 year high of $7.32. Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last posted its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.11. As a group, equities research analysts expect that Abeona Therapeutics Inc will post -1.16 earnings per share for the current fiscal year. Wall Street Analysts Forecast Growth A number of research firms have issued reports on ABEO. Stifel Nicolaus cut their price target on Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Alliance Global Partners restated a “buy” rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. HC Wainwright upped their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, April 30th. Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 15th. Finally, Oppenheimer began coverage on Abeona Therapeutics in a research report on Monday, June 2nd. They issued an “outperform” rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Abeona Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $19.25. Read Our Latest Stock Report on ABEO Insider Buying and Selling In related news, CFO Joseph Walter Vazzano sold 17,795 shares of the company’s stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $6.76, for a total value of $120,294.20. Following the completion of the sale, the chief financial officer now directly owns 491,246 shares of the company’s stock, valued at $3,320,822.96. This represents a 3.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the transaction, the chief executive officer now directly owns 1,355,322 shares of the company’s stock, valued at approximately $6,478,439.16. This trade represents a 1.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 113,941 shares of company stock valued at $711,341 in the last three months. 6.90% of the stock is owned by corporate insiders. Abeona Therapeutics Company Profile (Free Report) Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. See Also Five stocks we like better than Abeona Therapeutics About the Markup Calculator AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Canadian Penny Stocks: Can They Make You Rich? Casey’s Surges on Strong Q4, More Gains Likely Ahead Insider Trading – What You Need to Know Government Mandate Sends eVTOL Stocks Flying
https://www.defenseworld.net
- 1 week ago
8. Profile
Summary
Casey's General Stores, Inc. CASY
COUNTRY
US
INDUSTRY
Specialty Retail
MARKET CAP
$ 18.6 B
Dividend Yield
0.11%
Description
Casey's General Stores, Inc., together with its subsidiaries, operates convenience stores under the Casey's and Casey's General Store names. Its stores offer a selection of food, including freshly prepared foods, such as pizza, donuts, and sandwiches; beverages; tobacco and nicotine products; health and beauty aids; automotive products; and other nonfood items. The company's stores also provide motor fuel for sale on a self-service basis; and gasoline and diesel fuel. In addition, its stores offer various products, include soft drinks, energy, water, sports drinks, juices, coffee, and tea and dairy products; beer, wine, and spirits; snacks, candy, packaged bakery, and other food items; ice, ice cream, meals, and appetizers; health and beauty aids, electronic accessories, housewares, and pet supplies; and lotto/lottery and prepaid cards. Further, the company operates two stores that sells tobacco and nicotine products; one liquor store; and one grocery store. As of April 30, 2022, it operated 2,452 convenience stores. Casey's General Stores, Inc. was founded in 1959 and is headquartered in Ankeny, Iowa.
Contact
One SE Convenience Boulevard, Ankeny, IA, 50021
https://www.caseys.com
IPO
Date
Oct. 20, 1983
Employees
20935
Officers
Sanjeev Satturu
Senior Vice President & Chief Information Officer
Mr. Chad Michael Frazell
Chief Human Resources Officer
Mr. Brian Joseph Johnson
Senior Vice President of Investor Relations & Business Development
Mr. Stephen P. Bramlage Jr.
Senior Vice President & Chief Financial Officer
Ms. Ena Williams Koschel
Chief Operating Officer
Mr. Thomas P. Brennan Jr.
Senior Vice President & Chief Merchandising Officer
Katie Petru
Director of Communications
Ms. Katrina S. Lindsey
Chief Legal Officer
Mr. Darren M. Rebelez
President, Chief Executive Officer & Board Chair
Kory Ross
Vice President of Accounting